Pharma And Biotech CRM Software Market 2025

Pharma And Biotech CRM Software Market Size

The global pharma and biotech CRM software market reached a value of nearly $4,338.17 million in 2024, having grown at a compound annual growth rate (CAGR) of 9.15% since 2019. The market is expected to grow from $4,338.17 million in 2024 to $6,554.26 million in 2029 at a rate of 8.60%. The market is then expected to grow at a CAGR of 8.49% from 2029 and reach $9,850.68 million in 2034. Growth in the historic period resulted from the expansion of telemedicine and remote healthcare, growth in clinical trial activities, rising healthcare expenditure and growing demand for cloud-based solutions. Factors that negatively affected growth in the historic period were complex regulatory challenges and security and data privacy concerns. Going forward, the rise in chronic diseases, increasing client engagement activities, expanding global pharmaceutical sales force and favorable government initiatives will drive the growth. Factor that could hinder the growth of the pharma and biotech CRM software market in the future include resistance to digital adoption, talent shortages and impact of trade war and tariff.

Pharma And Biotech CRM Software Market Drivers

The key drivers of the pharma and biotech CRM software market include: Increasing Client Engagement Activities During the forecast period, the rise in client engagement initiatives is expected to fuel the growth of the pharma and biotech CRM software market. Pharmaceutical and biotech companies are increasingly strengthening their interactions with healthcare professionals (HCPs), patients, and partners through targeted digital channels, utilizing CRM software to automate and personalize communication efforts. These platforms streamline outreach across email, meetings, and social media, ensuring consistent messaging and well-coordinated follow-ups. By capturing and analyzing interaction data, CRM tools offer valuable insights into stakeholder behavior and preferences, supporting data-driven marketing strategies. Additionally, they aid in managing value-added services such as adherence programs and educational resources, enhancing both efficiency and effectiveness. As a result, CRM systems are becoming crucial for improving customer experience and driving operational excellence. The increasing client engagement activities contribution during the forecast period in 2024 is 2.00%.

Pharma And Biotech CRM Software Market Restraints

The key restraints on the pharma and biotech CRM software market include: Resistance To Digital Adoption Resistance to digital adoption is expected to hinder the growth of the pharma and biotech CRM software market during the forecast period. Many pharmaceutical and biotech companies continue to rely on paper-based or partially digital processes, with leadership often focusing more on regulatory compliance and scientific objectives than on digital transformation. As a result, CRM systems are frequently viewed as non-essential, delaying investment and slowing decision-making. Furthermore, a lack of in-house digital expertise—especially in CRM, data analytics, and cloud technologies—limits implementation capabilities and increases dependence on external vendors. Deploying CRM software also demands significant organizational change, which can be met with employee resistance due to uncertainty, inadequate training, or disruption of established workflows. In the absence of effective change management strategies, adoption rates remain low and system utilization limited. Growth affected by resistance to digital adoption during the forecast period in 2024 is -2.61%.

Pharma And Biotech CRM Software Market Trends

Major trends shaping the pharma and biotech CRM software market include: Integrating Electronic Health Records Into Pharma CRM Systems Major companies operating in the pharma and biotech CRM software market are increasingly integrating artificial intelligence (AI) and machine learning into their platforms to meet the rising demand for advanced, industry-specific customer engagement tools. AI-powered personalized engagement allows companies to deliver highly targeted and relevant communications to healthcare professionals (HCPs), patients, and other key stakeholders. For example, in October 2023, Salesforce Inc, a US-based cloud software provider, introduced its new Life Sciences Cloud, a secure platform for pharmaceutical (pharma) and medical technology (medtech) organizations. This platform leverages data, automation, and trusted AI to enhance patient engagement, streamline clinical operations, and manage the commercial lifecycle. It supports organizations in delivering personalized stakeholder experiences throughout the drug and device development process. The Life Sciences Cloud integrates data from multiple sources, including electronic health records and clinical trial systems, to provide a unified view of patients and providers. It also offers compliance tools tailored to the regulatory requirements of the healthcare industry. Strategic Partnerships Driving Innovation In Pharma And Biotech CRM Software Companies operating in the pharma and biotech CRM software market are adopting strategic partnerships approach to develop advanced solutions. Strategic partnerships help pharma and biotech CRM software companies by combining resources and expertise, enhancing research and development capabilities, expanding market reach, and accelerating commercialization, ultimately driving innovation and growth in the pharma and biotech CRM software industry. For example, in April 2024, Salesforce Inc, a US-based cloud software provider, partnered with IQVIA, a US-based provider of data, analytics, technology and services to the life sciences industry, to co-market a new CRM and other life sciences software. By combining Salesforce’s CRM and AI capabilities with IQVIA’s deep industry expertise and real-world data, the collaboration seeks to enhance commercial effectiveness, streamline clinical development, and improve patient outcomes. Additionally, in June 2022, Fujitsu, a Japan-based company operating in medical and pharmaceutical data and computing technologies, partnered with Salesforce Japan to develop have formed a strategic partnership to develop and commercialize personalized healthcare solutions for the Japanese market, with a particular focus on the insurance sector. The collaboration leverages Fujitsu's strengths in medical and pharmaceutical data management and advanced computing technologies alongside Salesforce's expertise in customer relationship management (CRM) and digital transformation for healthcare providers. Salesforce, a US-based cloud-based Customer Relationship Management (CRM) platform.

Opportunities And Recommendations In The Pharma And Biotech CRM Software Market

Opportunities – The top opportunities in the pharma and biotech CRM software market segmented by technology will arise in the conventional customer relationship management (CRM) segment, which will gain $1,451.52 million of global annual sales by 2029. The top opportunities in the pharma and biotech CRM software market segmented by deployment will arise in the cloud-based segment, which will gain $1,620.00 million of global annual sales by 2029. The top opportunities in the pharma and biotech CRM software market segmented by enterprise size will arise in the small and medium enterprises (SMEs) segment, which will gain $1,122.72 million of global annual sales by 2029. The top opportunities in the pharma and biotech CRM software market segmented by industry will arise in the pharma segment, which will gain $1,306.03 million of global annual sales by 2029. The pharma and biotech CRM software market size will gain the most in the USA at $553.92 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the pharma and biotech CRM software to focus on AI-driven personalization for stakeholder engagement, focus on generative AI integration to enhance CRM functionality, focus on artificial intelligence CRM for high-growth opportunities, focus on cloud-based CRM solutions to maximize growth, expand in emerging markets, continue to focus on developed markets, focus on optimizing multichannel distribution networks, focus on tiered pricing aligned with company size and compliance needs, focus on physician-centric promotional channels, focus on omnichannel digital campaigns and focus on customizing CRM engagement for biotech stakeholders.